Table 3 Frequency of mild-to-moderate adverse events on days 1–7 (related or not to treatment) with three artemisinin-containing combinations therapies in comparison with amodiaquine + sulphadoxine–pyrimathamine (AQ-SP)
AS-SMP | AS-AQ | AL | AQ-SP | p | |
|---|---|---|---|---|---|
N = 58 | N = 68 | N = 60 | N = 65 | ||
At least one adverse event | 24 | 35 | 17 | 32 | 0.037 |
% (95% CI) | 41% (29–55) | 51% (39–64) | 28% (17–41) | 49% (37–62) | |
Vomiting | 10 | 12 | 4 | 12 | 0.177 |
Fever | 11 | 14 | 8 | 6 | 0.143 |
Fatigue | 4 | 9 | 3 | 16 | 0.006 |
Abdominal pain | 3 | 8 | 2 | 9 | 0.112 |
Diarrhoea | 4 | 6 | 4 | 5 | 0.976 |
Anorexia | 3 | 4 | 3 | 8 | 0.377 |
Pruritus | 2 | 4 | 0 | 4 | 0.222 |
Drowsiness | 0 | 0 | 0 | 2 | 0.175 |
Aphthous stomatitis | 0 | 1 | 0 | 1 | 1.000 |
Headache | 1 | 0 | 1 | 0 | 0.359 |
Other* | 6 | 7 | 3 | 6 | 0.666 |